Category Archives: Epigenetics

The UN Climate Change Conference in Madrid opened on December 2 by calling the climate crisis a war against nature. But trees have always been at war, fighting for their survival. While plants may seem passive in the environment, they can sense their environments, make decisions, and respond to threatsup to a point.

Every autumn holds terrible perils for plants. While many trees drop their leaves every year, the decision of precisely when to do so is a delicate one, as Peter Wohlleben, a German forest ranger, explains in The Hidden Life of Trees. Too soon and trees lose the chance to make food for the coming spring. Too late and an early snow or ice storm can weigh down leaves, tear off branches, and cause fatal injuries.

That decision may seem automatic to a human observer, but individual trees actually make different calls, which shows how subjective the event is. Wohlleben describes 300-year-old oak trees growing side by side. One always sheds its leaves earlier than the others. The timing of leaf drop, it seems, really is a question of character, he writes. The tree on the right is a bit more anxious than the others, or to put it more positively, more sensible. The two others are bolder, he writes, gambling on good weather.

Also Read: Science Isnt the Only Way to Look at a Tree. Marvelling Is Another.

Trees decide when to act based on day length and temperature, which they can easily sense. Rising temperatures mean spring; falling temperatures mean fall. And what this proves as well, Wollenben writes, is that trees must have a memory.

This is quite different from the detailed and emotion-filled memories we recall every day, writes biologist Daniel Chamovitz in the book What a Plant Knows. Yet plants use some of the same mechanisms we do to recall events. Epigenetics is one major way that past experiences stay with us, such as tolerance for cold climatesand with plants, too.

Trees decide when to act based on day length and temperature, which they can easily sense. Credit: Creative Commons

Epigenetic changes affect the way genes are expressed without altering the underlying DNA code. The DNA is wrapped around proteins called histones, Chamovitz writes, and events can change certain histones, which in turn affect which genes turn on or off. In that way, plants remember things like bad weather and attacks by insects. Furthermore, they not only remember environmental stress but they can pass those memories on, because epigenetic changes are heritable. Their seeds come prepared for the problems their parents encountered.

That means they can recognise droughts and recall ways to cope. Trees can prepare to close the pores (stomata) on their leaves to limit water loss or grow fewer stomata, and can be ready to bring up more water from their roots. With something called somatic adaptation, the growing tips of branches can use a different phenotypethat is, change their actual physical formto cope with new anticipated growing conditions. This lets trees survive a wide range of environments. Trees, though we think of them as stationary and static, can use electrochemical gradients to move, as a Venus flytrap closes when an insect touches certain hairs in its trap. These gradients work like the electric signals in our nervous system.

But instead of a nervous system, any centralised source of decision-making, plants have what plant neurobiologist Stefano Mancuso, in The Revolutionary Genius of Plants, calls collective intelligence. Each part reacts to changes in its environment, including the changes in neighbouring parts of its own organism, much like a colony of bees. Even though they have nothing akin to a central brain, Mancuso writes, plants exhibit unmistakable attributes of intelligence. They are able to perceive their surroundings with a greater sensitivity than animals do.

Chamovitz writes, intelligence is a loaded term, but plants are acutely aware of the world around them. They can sense different kinds of light, evaluate chemicals in the air including those emitted by other plants, distinguish different kinds of touches to their leaves, and locate gravity. And plants are aware of their past. They dont know us as individuals, but they know their environment, and people are part of this environment.

What they may not realise is how dramatically the human part of their environment is altering the rest. Winter comes later, spring comes earlier, storms come more erratically and cause more damage. Summers are hotter, and droughts occur more often and are more severe.

Also Read: How I Became a Tree is an Ode to All That is Neglected

Trees know how to adapt, but there is a limit, says Andrew Mathews, a professor of environmental anthropology at the University of CaliforniaSanta Cruz. His work emphasises forestry and sustainability. In Europe, the last ice age ended about 12,000 years ago, which is only 20 generations for trees, he says, so adult trees are out of sync anyway with the climate, but thats not their most immediate problem.

Trees dont live in climate. They live in weather, he says, and they can adjust several times in a lifetime to cope in ways that animals cant, dropping leaves earlier or later, changing the shape and texture of their leaves, altering structures in their trunks, or growing deeper or shallower roots. Trees can even migrate to better climate zones by sending seeds carried by winds or animals to sprout in new areas. But can they move fast enough? Even if they do, new habitats are limited. Trees in mountainous areas can migrate to higher latitudes as temperatures rise, but even if they move fast enough, they may be pushed upslope until they have nowhere else to go and will become extinct in that location, Mathews says.

Trees in mountainous areas can migrate to higher latitudes as temperatures rise. Photo: Samuel Ferrara/Unsplash

Even if plants do succeed in adapting to climate change by changing their location or schedule, theyre not alone in their biospheres. The flowers they may decide bloom earlier or later need pollinators. Will the bees, birds, butterflies, wasps, spiders, and flies move in tandem with the trees, and if they do, will they be on the same schedule? Scientists just dont know.

We can debate the definition of intelligence, but we know that trees can identify and solve problems in ways that we cant. They remember that spring is coming, and when it does theyll be ready to sense the weather and make their decisions in response. But what they dont know is that their decisions become more critical with every passing season and year. Our decisions are just as critical. But we know that we can foresee the futureand as smart as they are, the trees cant.

This piece was originally publishedonFutureTense, a partnership betweenSlatemagazine, Arizona State University, and New America.

Read the original here:
Trees of Knowledge - The Wire

CMI published a business research report on Epigenetics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20182026. Epigenetics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.

Click To Get Free PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1772

The worldwide Epigenetics Market report stresses the most recent advancements, development, new chances, and lethargic traps. It gives a comprehensive position of the worldwide Epigenetics Market. The Epigenetics Market research report covers the present scenario and the growth prospects of the global Epigenetics Market industry for 2018-2026. The report enlists several important factors, starting from the basics to advanced market intelligence which play a crucial part in strategizing. Epigenetics Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Epigenetics Market industry.

Leading Market Player Profile Included in This Report is: Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Most of the information assembled is exhibited in a graphical frame alongside the related measurements. The Epigenetics Market report exhibits the working of the fundamental market players, providers, and merchants in detail. The report likewise features the limitations and drivers affecting the Epigenetics Market.

The report likewise incorporates a fundamental profile and data of all the significant market players at present dynamic in the worldwide Epigenetics Market. The organizations canvassed in the report can be assessed based on their most recent advancements, monetary and business diagram, item portfolio, enter drifts in the market, long haul and here and now business methodologies by the organizations with the end goal to remain aggressive in the market.

Get Sample Copy with Graphs and Charts @ https://www.coherentmarketinsights.com/insight/request-sample/1772

Important Features of the Keword Market:

To build up a far-reaching, verifiable, every year refreshed and financially savvy data dependent on execution, capacities, objectives, and systems of the worlds driving organizations.

To help current providers reasonably evaluate their money related, advertising and innovative capacities opposite driving contenders.

To help potential market contestants in assessing imminent acquisitions and joint endeavor hopefuls.

To supplement associations inner rival data gathering endeavors by giving vital investigation, information understanding, and knowledge.

To distinguish the slightest focused market specialties with huge development potential.

Global Epigenetics Market: Regional Segment Analysis

North America (U.S., Canada, Mexico),

Europe (Germany, U.K., France, Italy, Russia, Spain etc),

South America (Brazil, Argentina etc)

Middle East & Africa (Saudi Arabia, South Africa etc).

Asia-Pacific (China, Japan, India)

In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2013-2018), Revenue Market Share (%) by Players (2013-2018) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/1772

Available Customizations

As per specific needs customizations of the given market data is also available. Talk to our research consultant to design an exclusive report as per your research needs like Regional and country-level analysis of market by end-use, detailed analysis and profiles of additional market players.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit This Blog: http://bit.ly/Rajkumar123

Go here to read the rest:
Epigenetics Market by Applications, Vertical Type, and by Regions, 20162026 (US$ Million) - Market Reports Observer

HOUSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, announced today the acceptance of an abstract at the Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic taking place Monday, December 16, 2019 at the Franklin Institute in Philadelphia, PA. The trial-in-progress poster presentation will include an overview of the ongoing Phase 1/2 clinical trial for Salarius lead drug candidate, Seclidemstat, a potent reversible LSD1 inhibitor being developed as a treatment for Ewing sarcoma, a rare pediatric bone cancer.

Details of the symposium and poster presentation are as follows:

Abstract Title: Trials in progress: A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcomaWhere: The Franklin Institute, 222 North 20th Street, PhiladelphiaWhen: Monday, December 16, 2019 at 8:30 a.m. EST to 7 p.m. ESTSymposium Website: Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

The Epigenetics Symposium is an ideal event to showcase our progress bringing our lead drug candidate, Seclidemstat, into the clinic and the impact it could have on Ewing sarcoma, a rare and deadly bone cancer that most often strikes children and young adults and for which there are no targeted therapies approved, stated David Arthur, Chief Executive Officer of Salarius Pharmaceuticals. Lysine demethylase enzymes are a well-known target for epigenetic-based drug development. We have developed Seclidemstat to be a differentiated LSD1 inhibitor, and we are excited that it has reached the clinical trial setting where its safety and therapeutic activity can be assessed. Research shows that LSD1 expression is elevated in 60% of Ewing sarcoma patients and correlates with poor patient prognosis and decreased overall survival. Given the potential of Seclidemstat to address this great unmet need, we look forward to releasing early cohort data next year from our Ewing sarcoma study and a Phase 1 study in advanced solid tumors.

About Salarius PharmaceuticalsSalarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. In some cancers, epigenetic regulators often become dysregulated and incorrectly turn genes on or off leading to cancer progression. Drugs that can safely modify the activity of these epigenetic regulators may correct the gene changes that are driving the disease. The companys lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for several cancers with high unmet medical need, with a second Phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as will, can, could, believe, plan, allow, expect, provide, able to, position, anticipate, progress, potential, and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding: the progress in bringing Seclidemstat into the clinic and the impact it could have on Ewing sarcoma; the development of Seclidemstat to be a differentiated LSD1 inhibitor; the potential of Seclidemstat; anticipated timing of release of early cohort data from the companys Ewing sarcoma study and a Phase 1 study in advanced solid tumors; the companys belief that Seclidemstat is one of only two reversible inhibitors of LSD1 currently in human trials and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies; and the companys development of Seclidemstat for several cancers with high unmet medical need, including prostate, breast and ovarian cancers. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of the company to raise additional capital to meet the companys business operational needs and to achieve its business objectives and strategy; the companys ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius to access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius cash resources; and other risks described in Salarius filings with the Securities and Exchange Commission, including those under the heading Risk Factors. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on managements assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Contacts Investor Relations LifeSci Advisors, LLCJeremy FefferManaging Director(212) 915-2568 jeremy@lifesciadvisors.com

Media Relations: Tiberend Strategic Advisors, Inc.Johanna BennettSenior Vice President (212) 375-2686 jbennett@tiberend.com

Go here to read the rest:
Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic -...

Epigenetics Market research now available at Brand Essence Research encompasses an exhaustive Study of this business space with regards to pivotal industry drivers, market share analysis, and the latest trends characterizing the Epigenetics industry landscape. This report also covers details of market size, growth spectrum, and the competitive scenario of Epigenetics market in the forecast timeline.

The Epigenetics Market Report provides key strategies followed by leading Epigenetics industry manufactures and Sections of Market like- product specifications, volume, production value, Feasibility Analysis, Classification based on types and end user application areas with geographic growth and upcoming advancement. The Epigenetics market report provides comprehensive outline of Invention, Industry Requirement, technology and production analysis considering major factors such as Revenue, investments and business growth.

Request for Sample of this Report@ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Sample

The well-established players in the market are:

This report for Epigenetics Market discovers diverse topics such as regional market scope, product market various applications, market size according to specific product, sales and revenue by region, manufacturing cost analysis, Industrial Chain, Market Effect Factors Analysis, market size forecast, and more.

Drivers & Hindrances of the Epigenetics market: How does the report explicate on the same

The report unveils the driving parameters affecting the commercialization chart of this industry.

The Epigenetics market research report further illustrates the various challenges that this market is prone to as well as its impact on the market trends.

An important aspect that the report sets focus on is the market concentration ratio for the predicted timeframe.

The geographical spectrum of the business and its consequence on the Epigenetics market:

The report segments the Epigenetics market into USA, Europe, Japan, China, India, South East Asia depending on the regional scope of this business

Extensive data about the product consumption across innumerable sections as well as the valuation developed by these regions is also explained in the report.

The study puts emphasis on data concerning the consumption market share across these regions, as well as the market share attained by every region and product consumption growth rate.

Market segment by Type, the product can be split into

Market segment by Application, split into

Market segment by Regions/Countries, this report covers

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Request Customization of this Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Methodology

Key highlights and essential features of the report:

1) Which major players are presently listed in the report?Here are the companies that are presently listed in the report: Abcam Plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Epizyme Inc., Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation others.

**List of the firms stated above might differ in the final report dependent on a merger, name change, and other factors.

2) Can you list or add new firms as per our requirement?Yes,we can list or add new firm as per the requirement by client in the report. The final confirmation regarding the same must be provided by the research team subject to difficulty of survey.

**Availability of data will be confirmed after research in case of a privately held firm. Maximum 3 companies can be included at no additional charge.

3) Which all regional categorization are covered? Is it possible to add any specific country?Presently, our research report offers special focus and attention on the following areas:Europe, United States, Japan, China, India, Southeast Asia, and Central & South America

**Maximum one country of specific interest can be added at no extra charge. Charges will be applied for the addition of extra countries or regions.

4) Can the addition of extra Market breakdown or segmentation is possible?Yes, the addition of extra Market breakdown or segmentation is possibly dependent on the difficulty of survey and availability of data. On the other hand, detailed sharing of the requirements with our research team is a must before providing final confirmation to the client.

More Details on this Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Customization

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Epigenetics Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Epigenetics Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Epigenetics Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Epigenetics Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Epigenetics Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Epigenetics Market.

Market Forecast:Here, the report offers a complete forecast of the global Epigenetics Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Appendix:Here, we have provided a disclaimer, our data sources, data triangulation, research programs, market breakdown and design, and our research approach.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact US:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.

Kemp House, 152 160 City Road, London EC1V 2NX

+44-2038074155

sales@brandessenceresearch.com

View post:
Epigenetics Market Size Analysis, Application Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2019 To 2025 - The Market Stats News

Christmas Is A Season Not Only Of Rejoicing But Of Reflection. Avail Up To 40% Off On All Our Qualitative Research Reports. Be the Santa of Your Happy Business!

Worldwide Epigenetics Market is a report created by Global Marketers.Biz. The Epigenetics market research report is segmented on the basis of device, technology, application, and region. Primary and secondary research efforts were invested to arrive at intelligent conclusions presented in the report on the global target market. Findings and conclusions of the research were verified by experts from the industry before including it in the report.

It is a compilation of analytical study based on historical records, current, and upcoming statistics and future developments of the Epigenetics Industry. Based on the study, Global Marketers.Biz predicts that the market will see a comparable and steady CAGR growth.

Epigenetics Market Segmentation By Type, Applications & Regions

Fill Out Details To Receive FREE Sample Report Copy Here: https://www.globalmarketers.biz/report/life-sciences/global-epigenetics-industry-market-research-report/2687 #request_sample

The report covers a forecast and an analysis of the Epigenetics Market on a global and regional level. The ancient data is given from 2013-2018 and the estimate period is from 2019-2023 based on revenue (USD Billion). The Epigenetics market was estimated at XX Million US$ in 2019 and is probable to grasp XX Million US$ by 2023, at a CAGR of XX% throughout 2019-2023.

The study is also compiled on the basis of the latest and upcoming innovations, opportunities and trends. In addition to SWOT analysis, the report also contains a detailed market analysis outlining every major player in the process.

Avail Up To 40% Off On All Our Qualitative Research Reports.

Inquire Before Buying Or Ask For More Details: https://www.globalmarketers.biz/report/life-sciences/global-epigenetics-industry-market-research-report/2687 #inquiry_before_buying

The Report Answers the key Questions related to the Epigenetics Market:

What are the important trends and dynamics?

Where will most development take place in the long term?

What does the competitive landscape look like?

What the openings are yet to come?

TOC of Epigenetics Market Report Includes:

1. Industry Overview of Epigenetics

2. Industry Chain Analysis of Epigenetics

3. Manufacturing Technology of Epigenetics

4.Major Manufacturers Analysis of Epigenetics

5. Global Productions, Revenue and Price Analysis of Epigenetics by Regions, Creators, Types and Applications

6. Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Epigenetics 2013-2019.

7. Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Epigenetics by Regions

8. Gross and Gross Margin Examination of Epigenetics

9. Marketing Traders or Distributor Examination of Epigenetics

10. Worldwide Impacts on Epigenetics Industry,

11. Development Trend Analysis of Epigenetics

12. Contact information of Epigenetics

13. New Project Investment Feasibility Analysis of Epigenetics

14. Conclusion of the Global Epigenetics Industry 2019 Market Research Report

Continued

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Customization Service of the Report:

Global Marketers.biz provides customization of reports as per your need. The report can be altered to meet your requirements. Contact our sales team, who will guarantee you to get a report that suits your needs.

Please get in touch with our sales squad (Alex@globalmarketers.biz).

For more relevant information visit https://www.globalmarketers.biz/

Avail Up To 40% Off On All Our Qualitative Research Reports.

Request for more detailed information (TOC and Sample): https://www.globalmarketers.biz/report/life-sciences/global-epigenetics-industry-market-research-report/2687 #table_of_contents

Here is the original post:
Global Epigenetics Market | 2018-2023 Growth Analysis, Business Opportunities, Sales, Revenue, Gross Margin, Advance Technology and Application...

9 December 2019

For the first time US researchers have shown that not only genetics but a different level of developmental regulation called epigenetics impacts the innate drive of mice to exercise.

Epigenetics is a molecular mechanism within cells that controls which genes are transcribed and which ones are not, determiningwhich genes are 'turned on'and which ones are 'turned off'.

In this study the scientists found that the methylation of DNA, a process which is known to 'turngenes off', in some neurons in the hypothalamus leads to a decrease in exercise activity.

Corresponding author, Dr Robert Waterland, professor at the USDA/ARS Children's Nutrition Research Centre at Baylor and Texas Children's Hospital said: 'We study developmental programming, which refers to how the environment during development can have a long term impact on risk of diseaseour earlier findings suggested that establishment of one's physical activity 'set point'can be affected by early environment, and that this may involve epigenetics.'

Epigenetics is more malleable than genetics and could potentially be altered to increase exercise activity. The scientists investigated a specialised class of neurons in the hypothalamus called AgRP neurons which regulate food intake.

They disabled a gene causing DNA methylation in the AgRP neurons of mice and then tested whether these changes in methylation altered the weight of the animals. Interestingly, they discovered that mice with the disabled gene were slightly heavier.

Intriguingly, the animals did not eat more food than the ones with unchanged DNA methylation. However, the researchers did find a major difference in spontaneous physical exercise. Measuring the distance that the mice ran on a running wheel showed that normal mice ran on average 6 kilometres per night, while the methylation-deficient ones only ran half as much, and thus lost less weight. Notably, the epigenetic changes seemednot to impact the physical ability of the animals to run, but the desire to exercise.

'Our findings suggest that epigenetic mechanisms, such as DNA methylation, that are established in the brain during fetal or early postnatal life, play a major role in determining individual propensity for exercise,'Waterland said. 'Nowadays, as decreases in physical activity contribute to the worldwide obesity epidemic, it is increasingly important to understand how all of this works.'

The work was published in Nature Communications.

Read more:
'Couch potato' mice reveal that epigenetics affects urge to exercise - BioNews

Konstantinos Tzelepis, PhD, presented award-winning abstract on METTL3

CAMBRIDGE, England, Dec. 9, 2019 /PRNewswire/ -- STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics announces today, that its collaborator Dr. Konstantinos Tzelepis, Sir Henry Wellcome Fellow and visiting scientist at the Wellcome Sanger Institute, received the ASH-BSH Abstract Achievement Award for his work on STORM Therapeutics' lead programme, METTL3, at the 61st Annual Meeting of the American Society of Hematology (ASH) held on 7th-10th December 2019 in Orlando, Florida.

Dr. Tzelepis received the meritorious award for his abstract entitled 'Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutics Strategy for Acute Myeloid Leukemia'at the Abstract Achievement Award Ceremony which was held on Saturday, 7th December 2019 at 3:30pm (EST) at the Orange County Convention Center in Exhibit Hall B2-B4.

Dr. Tzelepis's work, which was carried out in collaboration with the Wellcome Sanger Institute and the University of Cambridge, was presented in an oral presentation during the "802. Chemical Biology and Experimental Therapeutics: Novel Compounds and Mechanisms of Action" session on Sunday, 8th December 2019 at 9:30am-11:30am (EST) at the Orange County Convention Centre. The abstract and talk encapsulated the ground-breaking work made on targeting RNA modifying enzymes for cancer treatment and described the recent progress made with the METTL3 inhibitor.

STORM has identified small molecule inhibitors of METTL3 that are orally bioavailable and show pronounced anti-tumour efficacy in physiologically relevant, proof of concept animal models of Acute Myeloid Leukaemia (AML). The talk demonstrated that small molecule inhibition of METTL3 produces the same phenotype and effects previously described in one of STORM's founder scientists' publications using genetic models and validates METTL3 as a druggable target for cancer.

Keith Blundy, CEO of STORM Therapeutics, said:"STORM is progressing fast in its preclinical work with our multiple programmes to showcase the capabilities of our novel platform. STORM is a pioneer in RNA epigenetics and we are very pleased to hear that our collaborator is being recognized for the partnership research of METTL3. As the first company in the world to demonstrate in vivo activity of an RNA methyltransferase inhibitor, we are excited to be leading the field as we look to develop these highly innovative new treatment options for cancer patients."

About STORM

STORM Therapeutics, founded in 2015, is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. Storm is the leading company tackling disease through modulating RNA modifying enzymes and is developing a unique platform and pipeline to address these enzyme classes, including RNA methyltransferases.

STORM is backed by blue chip investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences and IP Group, who share the team's ambitions to build a world-leading company in the field.

The Wellcome Sanger Institute

The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at http://www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.

SOURCE STORM Therapeutics

Excerpt from:
STORM Therapeutics' Collaborator Awarded ASH-BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition - PR Newswire UK

The Epigenetics Market report contains wide-extending factual assessment for Epigenetics, which enables the customer to separate the future complicity and estimate right execution. The advancement rate is evaluated dependent on insightful examination that gives the credible information on the worldwide Epigenetics market. Imperatives and advancement points are merged together after a significant comprehension of the improvement of Epigenetics market. The report is all around made by considering its essential information in the overall Epigenetics market, the essential components in charge of the interest for its products and administrations. Our best analysts have surveyed the Epigenetics market report with the reference of inventories and data given by the key players(Abcam, Novartis, Roche, Active Motif, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Diagenode, Inc., Illumina, Merck & Co., Inc., Thermo Fisher Scientific, New England Biolabs, Inc., Perkinelmer, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Zymo Research Corp.), flexible sources and records that help to upgrade cognizance of the related methodological conditions.

Ask for sample link here: http://www.extentresearch.com/request-for-sample.html?repid=2351

The Epigenetics market report shows a point by point division (Kits, Reagents, Enzymes, Instruments) of the overall market reliant on development, product type, application, and distinctive techniques and systems. The point-to-point elucidation of the Epigenetics market's assembling system, the usage of advancement, conclusions of the world market players, dealers and shippers' order, and the explicit business data and their improvement plans would help our customers for future courses of action and movement planned to make due in the Epigenetics market.

The Epigenetics market report includes the latest mechanical enhancements and new releases to engage our customers to the configuration, settle on taught business decisions, and complete their required executions in the future. The Epigenetics market report moreover focuses more on current business and present-day headways, future methodology changes, and open entryways for the Epigenetics market. Nearby progression frameworks and projections are one of the key segments that clear up overall execution and incorporate key geological analysis (Cancer, Metabolic Diseases, Immune Diseases, Cardiovascular Diseases, Others).

Inquire about the report here: http://www.extentresearch.com/inquiry-for-buying.html?repid=2351

The overall Epigenetics market is made with the fundamental and direct conclusion to exploit the Epigenetics market and participate in business progression for imperative business openings. The correct figures and the graphical depiction of the Epigenetics market are shown in a represented strategy. The report shows an examination of conceivable contention, current market designs and other basic characteristics all around the world.

Research Objective :

Our panel of trade contributors moreover as trade analysts across the worth chain have taken vast efforts in doing this group action and heavy-lifting add order to produce the key players with useful primary & secondary data concerning the world Epigenetics market. additionally, the report additionally contains inputs from our trade consultants that may facilitate the key players in saving their time from the interior analysis half. firms WHO get and use this report are going to be completely profited with the inferences delivered in it. except this, the report additionally provides in-depth analysis on Epigenetics sale moreover because the factors that influence the shoppers moreover as enterprises towards this method.

About UsExtent Research provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library includes industry & country research reports covering micro markets. This comprehensive collection of market research reports include market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more

Sorry! The Author has not filled his profile.

Go here to read the rest:
Global Epigenetics Market Growth 2019-2025 Abcam, Novartis, Roche, Active Motif, Inc., Agilent Technologies, Inc. - Exclusive Industry Reports

You may have your new years resolutions sorted but following through with your most ambitious fitness goals could be down to genetics.

By Mike Huyhn

Posted on December 6, 2019

Talk about a rude awakening. As another new year rounds the bend there are no doubt plenty of people plotting their annual fitness goals which they will never actually fulfil. You hopeful tragics get an A for effort.

Have you ever wondered though why its easier for the dedicated gym junkies to lift, run, bike and swim on a regular basis whilst others find it hard to get off the couch at all?

Researchers from the Baylor College of Medicine did and thats why they conducted a study to find out why this distinction in motivational behaviour between the dedicated and the lazy existed. The results from the study found that its not really your fault if you cant be bothered gyming its all in your genes.

The research entitled DNA methylation in AgRP neurons regulates voluntary exercise behaviour was published in Nature Communications. It highlights the epigenetic control of the expression of certain genes. These particular epigenetic mechanisms are explained to be more malleable than pure genetics alone, suggesting that there is still a way to program people into being more physically driven rather than just blaming genetics.

How they reached this conclusion was through the creation of an epigenetic couch potato mouse. In this test subject, the researchers analysed changes in the DNA methylation in neurons within the hypothalamus. Basically science jargon which says they found a link between the couch potato mouse and voluntary exercise behaviour.

Our earlier findings suggested that establishment of ones physical activity set point can be affected by early environment, and that this may involve epigenetics, explained corresponding author Robert A. Waterland, PhD, professor of pediatrics nutrition at the USDA/ARS Childrens Nutrition Research Center at Baylor and Texas Childrens Hospital.

Further investigations were conducted to test whether DNA methylation in the brain affects energy balance. Researchers implemented running cages in the animals cages for eight weeks and observed the difference between two specific groups. The normal male mice ran approximately 6km every night whilst the mice with a specific gene blocked only ran half the distance. Naturally the latter group also lost less fat.

What the researchers concluded from the experiment was that the gene-deficient mice were capable of running the same distance as normal mice but simply lacked the desire to.

Our findings suggest that epigenetic mechanisms, such as DNA methylation, that are established in the brain during fetal or early postnatal life, play a major role in determining individual propensity for exercise, Waterland said.

Nowadays, as decreases in physical activity contribute to the worldwide obesity epidemic, it is increasingly important to understand how all of this works.

Go here to see the original:
Researchers discover why youre skipping the gym for Netflix and sleep - The CEO Magazine

Epigenetics, or the study of biological changes that occur due to different chemical marks that alter the expression of our genes, proves that the beneficial effects of yoga penetrate deep into our minds and bodies and may even touch the very code of life that makes us who we are.

Do you feel stressed too often? Dont worry, youre not alone. The growing number of mentalhealth cases in India are pointing in the direction of a pressing need for attention. Research hasfound the top few sources of increasing stress in the lives of over one billion Indians to be money,work, family responsibilities, and health concerns.

Too much stress can take a significant toll on ones health. Not being able to copewith stress can lead to chronic diseases and accelerated ageing (but dont think about that toomuch, or risk adding it to your already lengthy list of issues inducing stress). If you have been trying to takemeasures to reduce therapy and have not achieved the desired outcome, there is still hope.

Epigenetic research has found that the ancient art of meditation, particularly mindfulmeditation, has numerous health and stress-reducing benefits.Yoga is the most ancient form of basic human wellness or unity of mind-body or in biologicalterms state of homoeostasis Homeo (resembling) stasis (equilibrium). In this state, all chemicalsand biochemicals in the body are in absolute balance state. All hormones calibrated (no excess orlittle testosterone, estrogen, cortisol), no excess or little adrenaline, dompamine(feel good) purged of all environmental toxins. Yoga helps in rhythmicbreathing which allows mind-body calibration resulting inneuroplasticity that fine tunes the brain or CNS to get calmer.

(The author isfounder,Vantage Enterprise)

More:
Get to the core with epigenetics - Deccan Herald